New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Business Wire
In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III settingSAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity WILMINGTON, Del.--(BUSINESS WIRE)--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include:LAURA Phase III trial of TAGRISSO in unre
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Chinese President Xi meets with global CEOs as investment wanes [Yahoo! Finance]Yahoo! Finance
- How AZ and Amgen's Tezspire respiratory data ups the ‘level of ambition' in immunology [Yahoo! Finance]Yahoo! Finance
- Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know [Yahoo! Finance]Yahoo! Finance
- J&J boasts Rybrevant, Lazcluze combo bests AstraZeneca's Tagrisso [Seeking Alpha]Seeking Alpha
- Keymed Biosciences Announces Annual Results of 2024 [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 3/21/25 - Form 6-K
- 3/17/25 - Form 6-K
- 3/17/25 - Form 6-K
- AZN's page on the SEC website